Imeik Technology Development Co., Ltd. is a Chinese company engaged in the research, development, and transformation of biomedical materials and biopharmaceutical products. It offers aesthetic medicine products, including cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere, poly facial implant thread, medical sodium hyaluronate-hydroxypropyl methylcellulose gel, sodium hyaluronate composite solution for injection, modified sodium hyaluronate gel for injection, medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel, and skin care products. The company serves medical aesthetic institutions. Incorporated in 2004, it is headquartered in Beijing, China.
Nhua Pharmaceutical's investee Haoxinqing plans to bring in 262 million yuan in capital increase, stepping up AI psychological companion robots
Nhua Pharmaceutical announced on September 29 that its investee Haoxinqing plans to raise 262 million yuan by issuing 7.77 million shares, bringing in seven new shareholders: Anjiemude, Imeik, Wuxi Dingqi, Zhangzhou Jiulongjiang, Zhangzhou Gaoxin, Shanjin Asset Management, and Unifuture. Nhua Pharmaceutical waived its preemptive right to subscribe in this capital increase, and its shareholding will fall from 19.10% to 18.04%, while it remains the largest shareholder of Haoxinqing. Haoxinqing is an AI-driven mental health and medical technology group, with businesses covering digital healthcare, a network of psychiatric and psychological doctors, offline specialty clinics, corporate mental health services, and AI technology solutions. The funds raised this time will be used mainly for AI psychological companion robots, diagnostic technology, and the digitalization of the psychological and medical health industry. In the first half of 2026, Nhua Pharmaceutical achieved revenue of 3.218 billion yuan and net profit attributable to the parent of 741 million yuan.
002262.CS · Capital · Neutral Nhwa waives its preemptive right in Haoxinqing's 262M yuan capital increase, diluting its stake from 19.10% to 18.04% while remaining largest shareholder.
300896.CS · Capital · Positive Imeik is named as one of seven new shareholders participating in Haoxinqing's 262M yuan capital increase.
Imeik Subsidiary Obtains Drug Registration Certificate for Lidocaine and Tetracaine Cream
Imeik announced on September 28 that its wholly owned subsidiary Beijing Nuobote Biotechnology Co., Ltd. recently received the Drug Registration Certificate for lidocaine and tetracaine cream approved and issued by the National Medical Products Administration. The drug is a prescription medicine indicated for intact skin in adults, mainly for local analgesia, with specific indications including dermal filler injections, pulsed dye laser treatment and other medical aesthetics procedures. In the first half of 2026, Imeik achieved revenue of 1.216 billion yuan and net profit attributable to the parent company of 593 million yuan.
300896.CS · Regulation · Positive Wholly owned subsidiary received NMPA Drug Registration Certificate for lidocaine and tetracaine cream, expanding its medical aesthetics product portfolio.
Imeik's first-half net profit plunges 24.84 percent as selling expenses surge 63 percent
Imeik released its 2026 semi-annual report. In the first half, it achieved operating revenue of 1.216 billion yuan, down 6.42 percent year on year, and net profit attributable to shareholders of the listed company of 593 million yuan, down 24.84 percent year on year. Net cash flow from operating activities was 535 million yuan, down 18.32 percent year on year, and the weighted average return on equity fell to 7.62 percent from 10.10 percent in the same period last year. By product, solution-based injectable products generated revenue of 591 million yuan, down 20.51 percent year on year, gel-based injectable products generated 379 million yuan, down 23.08 percent, and freeze-dried powder injectable products generated 209 million yuan, surging 973.50 percent year on year. Selling expenses reached 235 million yuan, soaring 62.89 percent year on year, while administrative expenses rose 36.48 percent year on year. Rapidly expanding costs are eroding profit margins. Goodwill at the end of the period stood at 1.641 billion yuan, accounting for 17.88 percent of total assets. Of this, goodwill of 1.305 billion yuan was formed from the acquisition of South Korea's REGEN. If operations fall short of expectations, an impairment will be recognised. The company plans to distribute a cash dividend of 10 yuan, before tax, for every 10 shares to all shareholders.
Aimeike's first-half net profit fell 24.84% year on year; plans dividend of 10 yuan per 10 shares
Aimeike disclosed its 2026 half-year report. In the first half, it achieved operating revenue of 1.216 billion yuan, down 6.42% year on year. Net profit attributable to shareholders of the listed company was 593 million yuan, down 24.84% year on year. Basic earnings per share were 1.97 yuan. The company plans to distribute a cash dividend of 10 yuan, tax included, for every 10 shares.
Imeik's Controlling Subsidiary Plans to Invest 30 Million Yuan in AI Large Model Fund
Imeik announced that its controlling subsidiary, Yuanzhimei, as a limited partner, plans to invest 30 million yuan in Hefei Haolan Chaozhi Venture Capital Partnership, with a tentative subscribed capital contribution ratio of about 4.29%. The fund's target total subscribed capital is tentatively set at 700 million yuan, and its investment direction is projects related to the AI large model field. One of the co-investors in this investment, Yao Jing, is the spouse of the company's actual controller and chairman, Jian Jun, which constitutes a connected transaction.
Aimeike Receives Medical Device Registration Certificate for Sodium Hyaluronate Gel
Aimeike has obtained a medical device registration certificate from the National Medical Products Administration for its medical cross-linked sodium hyaluronate-hydroxypropyl methylcellulose gel. The registration is valid from July 28, 2026, to July 27, 2031. In the first quarter of 2026, the company achieved revenue of 634 million yuan and a net profit attributable to the parent company of 298 million yuan.
Imeik Says Botulinum Toxin Product Not Yet on the Market
Imeik stated on an interactive platform that the company's botulinum toxin product has not yet been launched for sale, and the marketing and sales team is carrying out pre-launch preparations according to the established plan.
China